Prothena Biosciences Ltd.
Phase 1 Study of PRX019 in Healthy Adult Volunteers
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06699680
- Locations
- 🇺🇸
Local Institution, Los Alamitos, California, United States
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT04973137
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸St. Francis Hospital, Hartford, Connecticut, United States
🇺🇸Yale Cancer Center, North Haven, Connecticut, United States
Study in Subjects With Light Chain (AL) Amyloidosis
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT03154047
- Locations
- 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT02632786
- Locations
- 🇺🇸
Mayo Clinic - Minnesota, Rochester, Minnesota, United States
🇬🇧Centre for Clinical Haematology, Birmingham, United Kingdom
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT02613182
- Locations
- 🇺🇸
Stanford Cancer Institute (SCI), Stanford, California, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
- Conditions
- AmyloidosisAL Amyloidosis
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 343
- Registration Number
- NCT02574676
- Locations
- 🇺🇸
Online registry, South San Francisco, California, United States
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
- Conditions
- Primary Systemic (AL) Amyloidosis
- Interventions
- Other: Placebo
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT02312206
- Locations
- 🇫🇷
CHU Dijon - Hopital du Bocage, Dijon, France
🇺🇸Stanford Cancer Institute (SCI), Stanford, California, United States
🇫🇷Hopital de la Cote de Nacre Avenue, Caen Cedex 9, France
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT01707264
- Locations
- 🇺🇸
Stanford University Cancer Center, Palo Alto, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States